Skip to main content
. 2019 Nov 11;98(45):e17827. doi: 10.1097/MD.0000000000017827

Figure 2.

Figure 2

Survival curve of patients with different clinicopathologic parameters. (A) Age; (B) ECOG score; (C) cell of origin in all patients; (D) cell of origin in patients treated with HD-MTX based chemotherapies; (E) cell of origin in patients treated without HD-MTX based chemotherapies; (F) cell of origin in patients treated with HD-MTX based chemotherapies and rituximab; (G) BCL-2 protein; (H) c-MYC protein; (I) c-MYC and BCL-2 proteins.